Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

Some commonly available patient or disease characteristics may be associated with progression-free survival (PFS) and overall survival (OS) in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKIs (epidermal growth factor receptor - tyrosine kinase inhibitors). We performed a s...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Carlo Buonerba, Simona Iaccarino, Pasquale Dolce, Martina Pagliuca, Michela Izzo, Luca Scafuri, Ferdinando Costabile, Vittorio Riccio, Dario Ribera, Brigitta Mucci, Simone Carrano, Fernanda Picozzi, Davide Bosso, Luigi Formisano, Roberto Bianco, Sabino De Placido, Giuseppe Di Lorenzo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2019-08-01
Cyfres:Cancers
Pynciau:
non-small cell lung cancer
epidermal growth factor receptor tyrosine kinase inhibitors
sex
Mynediad Ar-lein:https://www.mdpi.com/2072-6694/11/9/1259
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg